Mylan, looking to capitalize on Biogen's Tecfidera patent loss, faces fork in the road on generic launch

Biogen took a major hit last week when a federal court tossed out its patent protections for multiple sclerosis drug Tecfidera. That loss could be Mylan's gain—but it would require the Pennsylvania generics maker to chance an "at-risk" launch, one analyst says.